Nursing Perspectives in Myelodysplastic Syndromes: Risk-Adapted Therapy and Symptom Management

Nursing Perspectives in Myelodysplastic Syndromes: Risk-Adapted Therapy and Symptom Management is organized by Medical Learning Institute Inc (MLI).

Release Date: Jun 15, 2026
Expiration Date: Jun 14, 2027

Description:
Nursing Perspectives in Myelodysplastic Syndromes: Risk-Adapted Therapy and Symptom Management is an interactive MLI Dialogues program recorded live at the Oncology Nursing Society (ONS) 2026 Congress in San Antonio, TX. This 90-minute on-demand session is designed for oncology nurses and nurse practitioners caring for patients with myelodysplastic syndromes and other hematologic malignancies.

Myelodysplastic syndromes (MDS) are complex hematologic malignancies requiring individualized, risk-adapted treatment and comprehensive supportive care. With rapid advances in targeted therapies, novel agents, and combination regimens for managing MDS-related anemia and cytopenias, oncology nurses must stay current with evolving treatment landscapes and evidence-based adverse event management strategies.

Captured at ONS 2026 in San Antonio, this engaging Dialogue features real-time audience interaction, expert discussion, and patient testimonials. Participants will review clinical and molecular factors essential to MDS risk stratification, explore current and emerging options for managing anemia in lower-risk MDS, and develop practical strategies for monitoring and mitigating treatment-related adverse events. The program emphasizes nursing-led approaches to patient education, shared decision-making, and supportive care interventions that improve treatment adherence, optimize quality of life, and support better patient outcomes across the MDS care continuum.

Learning Objectives:
After completing this activity, the participant should be better able to:

• Explain key clinical factors and cytogenetic/molecular biomarkers used in risk stratification and management of patients with lower-risk myelodysplastic syndrome (LR MDS) and higher-risk myelodysplastic syndrome (HR MDS)?
• Apply current and emerging therapeutic options for the management of anemia in patients with LR MDS, based on the latest data and evidence-based guidelines??
• Develop monitoring and management strategies for treatment-related adverse events and disease-related complications in patients with LR MDS??
• Implement nursing-led approaches to educate and counsel patients with LR MDS and equip them for productive shared decision-making encounters?